Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
about
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaMethodology in improving antibiotic implementation policiesBeyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing CarbapenemasesTreatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemComparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensAcinetobacter baumannii: emergence of a successful pathogenPharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy Chinese volunteers.New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsPK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration.Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniaeThe role of carbapenems in the treatment of severe nosocomial respiratory tract infections.Pharmacokinetic and pharmacodynamic properties of meropenem.Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review.Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns.Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options.Combination therapy for carbapenem-resistant Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Quantitative analysis of efficacy and associated factors of calcium intake on bone mineral density in postmenopausal women.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Impact of sample size on the performance of multiple-model pharmacokinetic simulations.Does prolonged infusion allow lower daily dose of meropenem than bolus dosing?Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae.Using Monte Carlo simulation to determine optimal dosing regimen for cefetamet sodium for injection.In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.Pharmacodynamics of SMP-601 (PTZ601) against vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in neutropenic murine thigh infection models.
P2860
Q24612271-DEA59A79-5976-46E5-AFBB-D9934A9FFE9DQ26744801-7E6BA73D-EB1F-41CA-B91E-B291319F7E36Q26747580-330AF017-C64A-4A5F-A89B-708B8A0EBC51Q28082546-5EF6CD28-65D5-46E8-AB0C-79DAB4698BA9Q28289744-7EEA0920-C53F-4887-AE49-D6BD6E9A3027Q33508985-15DAC990-2FAC-4993-8325-E80402612410Q33623060-576D8BB1-DB88-4C35-8D6E-E410B1B23CCDQ33770046-F63D2E3C-25D6-4A5F-8D4A-27139CC27E69Q34058137-A7F3A81C-BDBB-48E1-BCB2-412EF3189C2FQ34381321-9EFE8B69-B13A-47E4-909D-94724DBAC378Q34795807-2CF42262-011E-4974-B534-B28CC38BC565Q35076915-D39E80B1-B101-40FE-8221-D92231F8F457Q35616211-11FF01E0-9D80-4752-B1F6-5501C7EBE74EQ36083619-EA6E32E6-DBE0-4F40-A14F-01F3C3F03DE5Q36361921-5DA28127-B19C-4732-97A7-5D61765620A1Q36507959-D2CB273E-4A8A-4956-A9F4-9DD7C9799E94Q36582692-3515CF34-50B7-49F6-9027-65AE2C955EE3Q36633761-14B55422-9DB9-42FF-B1FD-5F50CF5A7FD3Q37023175-5177A7F6-C485-4561-9965-7B72A67E5ABDQ37098999-4E7D6816-ECA3-4492-9B76-FA6E00D299D2Q37247125-944663EA-D139-47EB-A721-E3D4449F6F83Q37538764-6C80CAB7-F237-4D34-8B77-7E2956E2F9ECQ37625193-531E0138-4135-4F1B-93CC-0A3F0FE4DD86Q37685856-1376D469-033F-447F-85B9-4D91AF899CABQ38001333-92580780-58F1-4990-987D-FB74351E1C2FQ38392082-E151C9E6-1BB7-4A31-86D0-49521634416AQ38585583-9FDFEA42-3521-4D36-9A4C-AC7647D014E7Q38672016-69689866-DEFE-4A0D-B168-7EDA81D61880Q38693420-A5D1EC21-3872-4DCD-8A5C-52644C210695Q38751264-85730E20-646F-43CC-8301-C84A2F7CA168Q38880620-F7306D9D-B949-421D-991B-50541382DDA4Q38944862-006D07C1-993D-4108-83CA-C45D2A2C4C21Q39078075-FFD4BC7F-5090-4C43-B24C-6CE4DE90709AQ39215434-7EBE9752-5916-4DBD-9089-5C471A2961E8Q40206253-DC7E6FFD-EC16-4A21-83D3-5E8A6A81353AQ41681159-E8173411-356E-488E-B670-E50882BE1F73Q41688964-0F80DD50-1B1E-482C-AAA3-FB22C2D9E781Q41727504-DD9AAAF7-0C39-434A-A141-EFF40CB12DAAQ41858894-86AC1E8E-B0EE-4E28-B55F-7F58F17EFB7BQ42111599-8F6DF27D-3B67-42CC-8EC7-65B1E5FFC900
P2860
Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Use of Monte Carlo simulation ...... dosing strategy for meropenem.
@en
Use of Monte Carlo simulation ...... dosing strategy for meropenem.
@nl
type
label
Use of Monte Carlo simulation ...... dosing strategy for meropenem.
@en
Use of Monte Carlo simulation ...... dosing strategy for meropenem.
@nl
prefLabel
Use of Monte Carlo simulation ...... dosing strategy for meropenem.
@en
Use of Monte Carlo simulation ...... dosing strategy for meropenem.
@nl
P2093
P2860
P356
P1476
Use of Monte Carlo simulation ...... dosing strategy for meropenem.
@en
P2093
Charles H Nightingale
David P Nicolau
Joseph L Kuti
Prachi K Dandekar
P2860
P304
P356
10.1177/0091270003257225
P577
2003-10-01T00:00:00Z